TERT and melanoma: Other TERT-derived synthetic peptides, that are presented by the major histocompatibility complex (MHC) and induce specific CD8+ cytotoxic T lymphocytes (CTL), include the peptide I540 (540-548; ILAKFLHWL), that is the first TERT immunogenic peptide identified as an HLA-A*0201-restricted T-cell epitope and has been evaluated in phase III clinical trials for melanoma treatment (Li et al., 2007; Wenandy et al., 2008; Liu et al., 2010).